Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

List making is ultimately a forward, affirmative act — the wish to impose order on a chaotic world. In that spirit, we ...

It was the year Newcastle United, Crystal Palace and Tottenham Hotspur fans experienced the joys of winning a trophy, the ...

:23 – Nope, not that one. Every one of Morton’s interceptions have been forced balls and there’s a dozen more close calls ...

President Trump announced on Monday the construction of a new “Trump class” of warships that would anchor what he called a ...

Excerpts from recent editorials in the United States and abroad: ___ Dec. 23 The Washington Post on conservatism and free markets When American conservatives abandon free-market principles, there’s no ...

A new study examining 218 mental health professionals in Spain reveals that recovery-oriented training doesn't impact ...

The world is a pretty fascinating place. But there are so many things happening all at once that you’d be forgiven for ...

When 67 electric cars were lined up in Inner Mongolia and sent out into temperatures around minus 25 °C, the test cut through ...

Utilize AI to analyze application runtime data (e.g., rendering time, communication latency), obtain optimization suggestions (such as reducing component re-rendering, reusing hardware connections), ...

Oracle Corporation, the database and cloud computing giant valued at more than $550 billion, has shifted its corporate ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...